RxDoctor Payments DataLook up a doctor →

Stephen Leblanc, MD

Allergy & Immunology · Meridian, MSNPI 1679837066

Payments from drug & device makers

$34,067in general payments, 2019–2025

Across 481 payments — averaging $70.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$13K
  • Biocryst Pharmaceuticals, Inc.$7K
  • Pharming Healthcare, Inc.$4K
  • AstraZeneca$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • plus $5K from 22 others

What the payments were for

  • Consulting fees$10,94232%
  • Speaking & faculty fees$7,70723%
  • Travel & lodging$4,97115%
  • Food & beverage$10,32830%
  • Education$1190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,067 in reported general payments places this provider in the 70th percentile of 28 allergy & immunology providers in Mississippi.

See all allergy & immunology providers in Mississippi

Medicare billing

Part B allowed, 2024
$490,457
Medicare patients
283
Services billed
17,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$55,511
TezspireTezepelumab-Ekko12$46,025
Dupixent PenDupilumab12$44,905
Spiriva RespimatTiotropium Bromide34$24,212
Breo ElliptaFluticasone/Vilanterol38$19,604
SymbicortBudesonide/Formoterol Fumarate49$14,198
Ipratropium Bromide448$12,854
Advair HfaFluticasone Propion/Salmeterol18$12,372
Fluticasone-SalmeterolFluticasone Propion/Salmeterol88$12,348
Azelastine Hcl253$7,784
BreynaBudesonide/Formoterol Fumarate25$4,874
Epinephrine24$4,533
Wixela InhubFluticasone Propion/Salmeterol18$3,301
Albuterol Sulfate HfaAlbuterol Sulfate116$2,908
Fluticasone Propionate146$2,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$1,376$75,115119 claims
AstraZenecaTezspire, Symbicort$1,970$60,22361 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 28 allergy & immunology providers in Mississippi.

Other allergy & immunology in Meridian

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →